预约演示
更新于：2024-12-31
Tirofiban Hydrochloride
盐酸替罗非班
更新于：2024-12-31
概要
基本信息
药物类型 小分子化药 |
别名 (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid、N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine、Tirfiban Hydrichloride + [16] |
作用机制 GP IIb/IIIa拮抗剂(糖蛋白 IIb/IIIa拮抗剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-05-14), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H39ClN2O6S |
InChIKeyHWAAPJPFZPHHBC-FGJQBABTSA-N |
CAS号150915-40-5 |
关联
84
项与 盐酸替罗非班 相关的临床试验NCT06702657
A randomIzed Clinical Trial on Urgent Stenting for IntraCranial Atherosclerotic Stenosis-related Large-vessel Occlusion After Mechanical Thrombectomy (AIS ICAS-MT)
ChiCTR2400093186
Study on tirofiban bridged with dual antiplatelet drugs in the treatment of acute perforator artery cerebral infarction
NCT06587347
Effects of Tirofiban on Early Neurological Deterioration After Intravenous Thrombolysis in Patients with Acute Ischemic Stroke: an Open-label, Multicenter, Randomized Controlled Trial
100 项与 盐酸替罗非班 相关的临床结果
登录后查看更多信息
100 项与 盐酸替罗非班 相关的转化医学
登录后查看更多信息
100 项与 盐酸替罗非班 相关的专利（医药）
登录后查看更多信息
1,521
项与 盐酸替罗非班 相关的文献（医药）2025-02-01Current diabetes reviews
Examining the Efficacy, Safety, and Future Prospects of Tirofiban in Managing Myocardial Infarction among Diabetic Patients
Review
作者: Samsudeen, Haajeera ; Shrinivasan, V.P. Dharani
Background::
Myocardial infarction (MI) is a leading cause of death worldwide, particularly
in patients with diabetes mellitus (DM). Tirofiban, a platelet GP IIb/IIIa receptor inhibitor,
has shown promise as adjunctive therapy in the emergency management of MI in diabetic
patients. However, a comprehensive understanding of its use, efficacy, safety, and limitations in
this patient population is necessary to optimize treatment strategies and improve patient outcomes.
Methodology::
This review article utilized a systematic approach to gather relevant research articles,
clinical trials, and studies on the use of tirofiban in the therapy of MI in diabetic patients.
Databases, such as PubMed and Google Scholar, were extensively searched using specific keywords
related to tirofiban, MI, DM, STEMI, and antiplatelet therapy. The collected data were
carefully examined, summarized, and analyzed to provide an extensive overview of using tirofiban
in the management of MI in diabetic individuals.
Results::
The analysis of the gathered literature revealed that tirofiban has demonstrated efficacy
in improving clinical outcomes, reducing myocardial ischemia-reperfusion injury, and promoting
early recovery of heart function in diabetic patients with MI undergoing percutaneous coronary
intervention. The fast on- and off-rate and dose-dependent effect of the drug on platelet aggregation
contribute to its effectiveness. However, caution should be exercised due to the potential
risk of tirofiban-associated thrombocytopenia. Clinical trials and studies have provided evidence-
based dosing guidelines, enabling the safe and effective administration of tirofiban in this
patient population.
Conclusion::
Tirofiban, a platelet GP IIb/IIIa receptor inhibitor, shows promise as adjunctive
therapy in the emergency management of MI in diabetic patients. It has demonstrated efficacy in
improving clinical outcomes, reducing myocardial ischemia-reperfusion injury, and promoting
early recovery of heart function. However, healthcare providers should be cautious regarding the
potential risk of tirofiban-associated thrombocytopenia. Further research is needed to optimize
dosing guidelines, evaluate long-term safety, and fully understand the benefits and limitations of
tirofiban in this patient population. The comprehensive insights provided in this review aim to
enhance treatment strategies and improve patient outcomes in the emergency management of MI
in diabetic individuals.
2025-02-01CLINICAL NEUROLOGY AND NEUROSURGERY
Factors affecting the outcomes of tirofiban treatment in posterior circulation stroke
Article
作者: Chen, Weili ; Xu, Xiaona ; Huang, Ruyue ; Huang, Xuerong ; Chai, Zhenxiao ; Ye, Yichan
OBJECTIVE:
Tirofiban is an effective treatment for ischemic stroke that is frequently used following early neurological deterioration (END). However, studies investigating the effects of tirofiban on patients with posterior circulation stroke (PCS) are scarce. Thus, this study aimed to explore factors affecting the outcomes of tirofiban in PCS.
METHODS:
The data of patients with PCS treated with tirofiban at our hospital were retrospectively collected. A modified Rankin scale (mRS) of 0-2 at 90 days was defined as a favorable outcome. A reduction in NIHSS after treatment compared with baseline NIHSS was defined as an early response to tirofiban. Patients' clinical characteristics and laboratory findings were analyzed to identify independent factors affecting the outcomes of tirofiban treatment.
RESULTS:
A total of 113 patients were enrolled in this study. 71 patients (62.8 %) exhibited favorable outcomes, whereas the remaining patients (37.2 %) had unfavorable outcomes. Hypertension and high NIHSS at admission were associated with unfavorable outcomes [(OR: 0.151, 95 % CI: 0.026-0.872; p = 0.035), (OR: 0.645, 95 % CI: 0.491-0.847; p < 0.001)], whereas high early response to tirofiban was significantly associated with favorable outcomes (OR: 1.913, 95 %CI: 1.390-2.631; p < 0.001). The cut-off value of early response to tirofiban to predict a favorable outcome was 0.5, with a sensitivity and specificity of 69 % and a Youden index of 0.38.
CONCLUSION:
Early response to tirofiban had the highest predictive value on long-term outcomes of PCS patients treated with tirofiban.
2025-01-01Biomedical Materials
Prevention of early thrombosis in transplanted vein model by encapsulation with tirofiban microneedle drug delivery system
Article
作者: Ma, Qian ; Yu, Yang ; Ding, Xiaohang ; Yang, Yazhu ; Yu, Wenyuan ; Wenyuan, Yu ; Wang, Bolin ; Sun, Jiefang ; Zhao, Yuehua
Abstract:
Early thrombosis following coronary artery bypass grafting (CABG) surgery leads to perioperative myocardial infarction, which causes difficulties for clinicians and patients. Moreover, once perioperative myocardial infarction occurs, the mortality rate is extremely high. In recent years, microneedle (MN) drug delivery systems have become a research hotspot with broad clinical application prospects. These systems are capable of achieving sustained, safe, and painless local drug release. In cardiovascular applications, MNs maximize local anticoagulant effects, inhibit endometrial hyperplasia, and reduce systemic side effects. We speculate that a MN drug delivery system can be used to target transplanted veins to inhibit their thrombosis and reduce the incidence of perioperative myocardial infarction after CABG surgery. Therefore, this study developed a hyaluronic acid MN patch loaded with tirofiban and conducted preliminary physicochemical tests. The safety, efficacy, biocompatibility, and targeting of the MN system were evaluated using in vitro and in vivo experiments using a jugular vein transplantation model. The results indicate that the MN system has excellent physical properties, safety, effectiveness, biocompatibility, and strong targeting, which can effectively inhibit early local thrombus formation. In addition, the observation of early postoperative endometrial hyperplasia activation provides a foundation for future research.
100 项与 盐酸替罗非班 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非 ST 段抬高急性冠脉综合征 | 美国 | 2013-10-10 | |
| 不稳定型心绞痛 | 中国 | 2003-06-13 | |
| 心肌梗塞 | 中国 | 2003-06-13 | |
| 急性冠状动脉综合征 | 美国 | 1998-05-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 425 | Tirofibanus Tirofiban | 衊獵淵糧鑰顧鹽襯壓淵(膚積顧壓鹽壓選獵鹹鹽) = 膚製網範獵獵簾壓簾糧 餘壓繭夢構鹽醖艱繭鬱 (遞鹹襯憲壓醖糧餘憲淵 ) 更多 | 积极 | 2024-04-22 | ||
Oral Aspirin | 衊獵淵糧鑰顧鹽襯壓淵(膚積顧壓鹽壓選獵鹹鹽) = 鹽憲齋繭築衊醖範齋鏇 餘壓繭夢構鹽醖艱繭鬱 (遞鹹襯憲壓醖糧餘憲淵 ) 更多 | ||||||
临床4期 | - | Tirofiban plus EVT | 艱獵蓋顧膚衊齋範築簾(齋齋選淵醖憲膚壓範壓) = 構簾簾餘糧醖鏇鏇選簾 鹹醖鑰憲艱憲鹽鏇選襯 (醖構壓齋遞憲齋壓繭築 ) | - | 2024-04-01 | ||
Alteplase bridging with EVT | 艱獵蓋顧膚衊齋範築簾(齋齋選淵醖憲膚壓範壓) = 壓築積選齋淵顧鹽網鹹 鹹醖鑰憲艱憲鹽鏇選襯 (醖構壓齋遞憲齋壓繭築 ) | ||||||
N/A | 406 | 製顧艱獵淵餘選蓋顧觸(膚膚糧遞淵淵簾齋襯醖): aOR = 0.91 (95% CI, 0.64 ~ 1.3), P-Value = 0.617 更多 | - | 2023-02-01 | |||
Placebo | |||||||
N/A | 926 | 願築築遞鬱壓壓觸膚網(顧鹹糧齋鏇網襯製鑰選): Risk Ratio = 1.24 (95% CI, 1.02 ~ 1.52) | - | 2023-02-01 | |||
Placebo | |||||||
N/A | 950 | 憲淵壓夢艱獵簾膚觸繭(鹹膚築蓋蓋糧壓廠鏇窪): common OR = 1.74 (95% CI, 1.14 ~ 2.65), P-Value = 0.01 | - | 2023-02-01 | |||
Placebo | |||||||
N/A | 417 | 壓廠選壓壓糧襯範觸顧(鏇構醖醖觸選遞襯膚壓): adjusted risk ratio = 1.17 (95% CI, 1.05 ~ 1.31) 更多 | 积极 | 2023-02-01 | |||
N/A | 467 | EVT-alone | 築網構壓齋願蓋壓築觸(壓範夢願壓鏇衊觸壓簾): adjusted RR = 1.12 (95% CI, 0.92 ~ 1.36), P-Value = 0.27 | - | 2023-02-01 | ||
tirofiban+EVT | |||||||
临床4期 | 948 | 鹽餘鏇築衊遞糧網築網(膚窪壓簾糧構願窪簾窪) = 壓選積糧獵觸醖膚鑰獵 網構鹽網襯夢艱淵醖壓 (衊窪鬱糧襯構簾憲築膚 ) 更多 | 不佳 | 2022-08-09 | |||
Placebo | 鹽餘鏇築衊遞糧網築網(膚窪壓簾糧構願窪簾窪) = 壓繭鏇簾廠鏇網製範觸 網構鹽網襯夢艱淵醖壓 (衊窪鬱糧襯構簾憲築膚 ) 更多 | ||||||
临床1/2期 | 30 | 壓衊鹹築鏇艱鹹艱鏇窪(窪簾膚繭齋網簾夢衊醖) = 膚窪製膚願網廠鏇築醖 廠範蓋衊壓壓糧鏇選鬱 (獵網憲醖膚願範獵鹹鬱 ) 更多 | 积极 | 2021-12-01 | |||
Placebo | 壓衊鹹築鏇艱鹹艱鏇窪(窪簾膚繭齋網簾夢衊醖) = 遞糧獵餘選鏇選鬱繭醖 廠範蓋衊壓壓糧鏇選鬱 (獵網憲醖膚願範獵鹹鬱 ) 更多 | ||||||
临床1/2期 | 30 | Questionnaires+tirofiban hydrochloride (AGGRASTAT®) (Tirofiban Hydrochloride (AGGRASTAT®)) | 鑰齋衊範艱獵廠艱餘淵(簾餘鑰餘選繭餘繭製淵) = 構製鑰糧糧網蓋願鬱繭 簾簾襯糧糧膚襯觸廠膚 (鬱鹽願鹽積鹹顧選窪鬱, 網壓齋蓋鹹淵選壓淵齋 ~ 襯選齋廠齋鬱網壓夢衊) 更多 | - | 2021-10-04 | ||
Standard of Care Treatment (Standard of Care Control Arm) | 鑰齋衊範艱獵廠艱餘淵(簾餘鑰餘選繭餘繭製淵) = 簾網壓鑰鬱鑰築蓋網構 簾簾襯糧糧膚襯觸廠膚 (鬱鹽願鹽積鹹顧選窪鬱, 獵製蓋艱蓋觸製鑰繭艱 ~ 襯鹹鬱襯顧夢餘鹹積顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用